CEL-SCI Corp
CEL-SCI Corp logo
CVM

CEL-SCI Corp (CVM)

$2.93.97%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.87
Day's Range
$3.09
$2.49
52-Week Range
$10.22
1 month return16.18%
3 month return26.4%
1 year return67.49%
5 year return59.34%

Company Information

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck, are treated with the investigational product Multikine first, BEFORE they received surgery, radiation and/or chemotherapy (the current standard of care for these patients). This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for the neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. CEL-SCI believes that this Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study’s protocol, newly diagnosed patients with advanced primary squamous cell carcinoma of the head and neck were treated with the Multikine treatment regimen right after diagnosis and prior to receiving the Standard of Care (SOC), which involves surgery, radiation or concurrent radiochemotherapy. Multikine is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body’s immune system prior to SOC to attack the cancer. The Phase 3 study is fully enrolled with 928 patients and the last patient was treated in September 2016. To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 (death) events have occurred among the two main comparator groups. This study milestone occurred in late April 2020. The study is currently in the statistical analysis phase. The Company’s LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment for COVID-19 infection. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.
OrganizationCEL-SCI Corp
Employees0
CEOMr. Geert R. Kersten Esq.
IndustryHealth Technology

Analyst Recommendation

based on 0 analysts ratings

Sell
0%
Buy
0%
Hold
0%
Sell

Based on 0 Wall street analysts offering stock ratings for CEL-SCI Corp(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 417.24%

Current

$2.9

Target

$15.0

Recommendation Trend

Based on 0 analyst

Current1M Ago3M Ago
Buy
0
4
4
Hold
0
1
1
Sell
0
0
0
Consensus
SELL
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
131.0M
Book Value
$0.89
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.87
PEG Ratio
0.0
Wall Street Target Price
15.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
3.14
Enterprise Value
109.0M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-3.49

Technicals

Beta
1.75
50 Day MA
3.25
200 Day MA
3.81

Discover more

Frequently Asked Questions

What is CEL-SCI Corp share price today?

Can Indians buy CEL-SCI Corp shares?

How can I buy CEL-SCI Corp shares from India?

Can Fractional shares of CEL-SCI Corp be purchased?

What are the documents required to start investing in CEL-SCI Corp stocks?

What are today’s High and Low prices of CEL-SCI Corp?

What are today’s traded volumes of CEL-SCI Corp?

What is today’s market capitalisation of CEL-SCI Corp?

What is the 52 Week High and Low Range of CEL-SCI Corp?

How much percentage CEL-SCI Corp is down from its 52 Week High?

How much percentage CEL-SCI Corp is up from its 52 Week low?

What are the historical returns of CEL-SCI Corp?

Who is the Chief Executive Officer (CEO) of CEL-SCI Corp?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*